FLT3 and acute myeloid leukemia: To address this topic and build upon our previously published work on FLT3-ITD+ AML patients carrying a co-operative NUP98-NSD1 gene fusion9, we performed a systematic analysis by integrating ex vivo drug sensitivity and resistance testing (DSRT) with FLT3 mutation fragment analysis, and next-generation sequencing (exome and RNA).